Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma

Cazzamalli, Samuele; Figueras Agustí, Eduard; Pethő, Lilla; Borbély, Adina Noémi; Steinkühler, Christian; Neri, Dario; Sewald, Norbert

Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma

Cazzamalli S, Figueras Agustí E, Pethő L, Borbély AN, Steinkühler C, Neri D, Sewald N (2018)
ACS Omega 3(12): 16743-16743.

Zeitschriftenaufsatz | Veröffentlicht | Englisch

Download

Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!

DOI

https://doi.org/10.1021/acsomega.8b03183

Autor*in

Cazzamalli, Samuele; Figueras Agustí, Eduard^UniBi; Pethő, Lilla; Borbély, Adina Noémi^UniBi; Steinkühler, Christian; Neri, Dario; Sewald, Norbert^UniBi

Einrichtung

Fakultät für Chemie > Organische Chemie III

Erscheinungsjahr

2018

Zeitschriftentitel

ACS Omega

Band

3

Ausgabe

12

Seite(n)

16743-16743

eISSN

2470-1343

Page URI

https://pub.uni-bielefeld.de/record/2944897

Zitieren

Cazzamalli S, Figueras Agustí E, Pethő L, et al. Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma. ACS Omega. 2018;3(12):16743-16743.

Cazzamalli, S., Figueras Agustí, E., Pethő, L., Borbély, A. N., Steinkühler, C., Neri, D., & Sewald, N. (2018). Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma. ACS Omega, 3(12), 16743-16743. doi:10.1021/acsomega.8b03183

Cazzamalli, Samuele, Figueras Agustí, Eduard, Pethő, Lilla, Borbély, Adina Noémi, Steinkühler, Christian, Neri, Dario, and Sewald, Norbert. 2018. “Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma”. ACS Omega 3 (12): 16743-16743.

Cazzamalli, S., Figueras Agustí, E., Pethő, L., Borbély, A. N., Steinkühler, C., Neri, D., and Sewald, N. (2018). Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma. ACS Omega 3, 16743-16743.

Cazzamalli, S., et al., 2018. Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma. ACS Omega, 3(12), p 16743-16743.

S. Cazzamalli, et al., “Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma”, ACS Omega, vol. 3, 2018, pp. 16743-16743.

Cazzamalli, S., Figueras Agustí, E., Pethő, L., Borbély, A.N., Steinkühler, C., Neri, D., Sewald, N.: Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma. ACS Omega. 3, 16743-16743 (2018).

Cazzamalli, Samuele, Figueras Agustí, Eduard, Pethő, Lilla, Borbély, Adina Noémi, Steinkühler, Christian, Neri, Dario, and Sewald, Norbert. “Correction: In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinoma”. ACS Omega 3.12 (2018): 16743-16743.

Daten bereitgestellt von European Bioinformatics Institute (EBI)